尚荣医疗
(002551)
| 流通市值：18.09亿 | | | 总市值：25.03亿 |
| 流通股本：6.11亿 | | | 总股本：8.45亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 835,644,818.35 | 565,715,471.76 | 257,385,011.97 | 1,077,302,804.42 |
| 营业收入 | 835,644,818.35 | 565,715,471.76 | 257,385,011.97 | 1,077,302,804.42 |
| 二、营业总成本 | 861,270,934.28 | 566,992,294.58 | 263,960,900.4 | 1,153,967,258.09 |
| 营业成本 | 716,701,515.08 | 475,785,009.46 | 219,474,770.56 | 949,336,499.65 |
| 税金及附加 | 16,571,162.58 | 10,249,797.4 | 4,917,687.18 | 28,897,271.76 |
| 销售费用 | 11,221,432.95 | 7,612,727.32 | 3,755,946.87 | 19,329,051.1 |
| 管理费用 | 99,707,730.23 | 64,508,904.53 | 32,179,531.11 | 126,305,019.4 |
| 研发费用 | 27,493,221.57 | 17,330,850.4 | 8,703,056.4 | 41,564,415.36 |
| 财务费用 | -10,424,128.13 | -8,494,994.53 | -5,070,091.72 | -11,464,999.18 |
| 其中:利息费用 | 1,343,790.62 | 1,516,767.63 | 368,350.88 | 15,607,225.18 |
| 其中:利息收入 | 16,613,390.44 | 4,811,263.78 | 2,008,517.48 | 7,434,538.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,717,564.66 | 3,233,020.24 | 1,578,451.1 | 824,808.57 |
| 加:投资收益 | 4,397,592.12 | 4,242,792.06 | 2,416,667.32 | 15,284,664.17 |
| 资产处置收益 | -23,058.81 | -23,058.81 | 28,777.61 | 10,104,229.32 |
| 资产减值损失(新) | 6,106.74 | 6,128.77 | 6,217.72 | -22,038,371.43 |
| 信用减值损失(新) | -14,667,346 | -14,418,209.79 | 1,902,641.66 | -84,302,732.78 |
| 其他收益 | 3,723,577.72 | 2,445,603.89 | 970,836.13 | 6,397,902.3 |
| 四、营业利润 | -27,471,679.5 | -5,790,546.46 | 327,703.11 | -150,393,953.52 |
| 加:营业外收入 | 2,349,010.13 | 2,339,891.34 | 36,788.19 | 5,386,507.31 |
| 减:营业外支出 | 1,567,486.17 | 76,881.19 | 84,900.31 | 12,573,434.53 |
| 五、利润总额 | -26,690,155.54 | -3,527,536.31 | 279,590.99 | -157,580,880.74 |
| 减:所得税费用 | 10,315,524.32 | 9,776,040.42 | 1,513,928.31 | -11,372,863.72 |
| 六、净利润 | -37,005,679.86 | -13,303,576.73 | -1,234,337.32 | -146,208,017.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -37,005,679.86 | -13,303,576.73 | -1,234,337.32 | -146,208,017.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -32,790,385.18 | -15,642,789.89 | -1,806,254.42 | -139,581,671.9 |
| 少数股东损益 | -4,215,294.68 | 2,339,213.16 | 571,917.1 | -6,626,345.12 |
| 扣除非经常损益后的净利润 | -42,214,600.55 | -23,282,925.36 | -5,508,541.18 | -162,768,657.06 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.04 | -0.02 | 0 | -0.17 |
| (二)稀释每股收益 | -0.04 | -0.02 | 0 | -0.16 |
| 八、其他综合收益 | -17,142,208.21 | -11,839,557.62 | -3,968,922.52 | -10,430,756.03 |
| 归属于母公司股东的其他综合收益 | -16,071,815.56 | -11,584,265.81 | -5,768,543.29 | -11,636,511.2 |
| 九、综合收益总额 | -54,147,888.07 | -25,143,134.35 | -5,203,259.84 | -156,638,773.05 |
| 归属于母公司股东的综合收益总额 | -48,862,200.74 | -27,227,055.7 | -7,574,797.71 | -151,218,183.1 |
| 归属于少数股东的综合收益总额 | -5,285,687.33 | 2,083,921.35 | 2,371,537.87 | -5,420,589.95 |
| 公告日期 | 2026-10-27 | 2026-08-25 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |